• 목록
• 답변

ARBORMED has signed Research Collaboration Agreement & Technology Transfer Agreement with Yonsei Medical Center for Acute Respiratory Distress Syndrome and Rare Diseases

ARBORMED (CEO Park Kyo-jin, CEO Wim Weonbin), an Innovative New Drug company that develops new drugs for incurable rare diseases, announced on the 22nd
 that it has signed a joint research and technology transfer contract with Yonsei Medical Center for the treatment of acute respiratory Distress syndrome and hereditary hearing loss.
Through this technology transfer, Arbormed will have the right to re-implement, develop, produce, and sell all of the results of research on treatments for acute respiratory distress syndrome
 and hereditary hearing loss, including new synthetic drugs discovered by Yonsei University's professor team.

This agreement is drawing attention from the pharmaceutical bio-industry as it is a case of collaboration between Korea's leading medical research institutes and innovative bio-ventures.
This is because if various research results of Yonsei Medical Center are commercialized through Arbormed, the burden on patients who have suffered from incurable or rare diseases for a long time
can be quickly reduced.

Acute respiratory distress syndrome (ARDS) is a difficulty in breathing caused by an accumulation of fluid in the lungs due to trauma, infection, and lung disease. Although the mortality rate
reaches about 40%, it is an intractable disease with high medical demand because there is no effective treatment yet.

Genetic hearing loss, which is accompanied by congenital hearing loss, is a disease that occurs in one to three out of 1,000 newborns, and most of them can lose their hearing by the age of five.
Hearing loss is known to be 10-15 percent of all deaf patients, which is more frequent than any other congenital disease such as Down syndrome and cleft palate.
In addition, ARBORMED has a promising new drug R&D pipeline, including Wilson's disease treatment, introduced by partners in the U.S. and Germany in the field of rare diseases.
Furthermore, it plans to use the infrastructure of its U.S. subsidiary, ARBOMED Pharmaceuticals, to speed up its entry into global markets by obtaining U.S. FDA permits and
negotiating drug prices.

The company was highly recognized for its innovation and business development ability, attracting a total of 12 billion won in investment through series A investment and strategic partnership
with Ildong Pharmaceutical. Based on the investment, the company is currently researching and developing new drug candidates for Wilson's disease with the aim of entering phase 1 clinical
trials in 2023 and transferring technology to multinational pharmaceutical companies in 2024. Wilson's disease is a disease in which copper accumulates in the liver and brain due to abnormalities
in copper metabolism in the human body.

Yonsei Medical Center has been conducting research on rare and chronic diseases with medical staff in various fields such as otolaryngology, cardiology, respiratory medicine, and urology
for the past few years. In particular, in December last year, animal models proved the efficacy of pendrin protein regulators in acute lung damage, acute respiratory failure syndrome,
and rare hereditary hearing loss diseases.

Choi Jae-young, a professor of otolaryngology at Yonsei Medical Center, said, "This joint research and technology transfer contract with Arbormed will be an opportunity to take a step further in developing treatments that patients need."